Researchers at the Icahn School of Medicine have unveiled the AMETA Nanobody Platform, which effectively combats SARS-CoV-2 and other rapidly mutating viruses. This new antibody approach utilizes engineered nanobodies targeting multiple stable virus regions, enhancing binding strength and resistance to mutations. The platform offers potential for broader infectious disease management, including HIV and influenza, with […]
Source link